Revenue
2022
2023
2024
2025
Ixico plc (IXI)
Price£0.1000Cached quote
Net income
2022
2023
2024
2025
Free cash flow
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | £6.5M | £5.8M | £6.7M | £8.6M |
| Research & development | £1.3M | £1.3M | £925,000 | £1.2M |
| Operating expenses | £5.7M | £4.8M | £4.6M | £4.3M |
| Operating income | −£2.5M | −£2.1M | −£1.4M | £908,000 |
| Operating margin | −38.51% | −36.46% | −20.29% | 10.51% |
| EBITDA | −£2.0M | −£1.6M | −£707,000 | £1.6M |
| EBITDA margin | −30.95% | −27.64% | −10.61% | 18.01% |
| Net income | −£1.7M | −£2.0M | −£1.2M | £1.0M |
| Net profit margin | −25.27% | −34.70% | −17.67% | 11.94% |
| Basic EPSper basic share | -£0.02 | -£0.04 | -£0.02 | £0.02 |
| Diluted EPSper diluted share | -£0.02 | -£0.04 | -£0.02 | £0.02 |
Owners
Reported major voting-rights holders
19.15%of voting rights
Octopus Investments LimitedNotified Apr 27, 2026
View holders
| Holder | Voting rights |
|---|---|
| 19.15%Apr 27, 2026 · 41.75M votes | |
| 3.95%Apr 27, 2026 · 8.61M votes |
These are threshold-crossing notices, not a complete ownership register. Percentages show issuer voting rights held through the listed share class, exclude financial instruments, and come from different dates. Positions may overlap.
Gray completes the 100% scale; it is not an estimate of other owners.
Source: FCA voting-rights notice ↗Updated Oct 21, 2026
Community posts
IXICO wins £1.5 million of Alzheimer’s imaging and biomarker work
IXICO ($IXI) secured two Alzheimer’s-related contracts with a combined value of approximately £1.5 million. One covers neuroimaging management and analysis for a biotechnology client’s Phase 2b study, with revenue expected over roughly thre ...
